Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2016 Jun 3;34(26):3001-5. doi: 10.1016/j.vaccine.2016.03.078. Epub 2016 Mar 31.

Advancing a vaccine to prevent hookworm disease and anemia.

Author information

1
National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA; Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development, Houston, TX, USA; Department of Biology, Baylor University, Waco, TX, USA; Sabin Vaccine Institute, Washington, DC, USA. Electronic address: hotez@bcm.edu.
2
National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development, Houston, TX, USA.
3
Sabin Vaccine Institute, Washington, DC, USA.
4
National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA; Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development, Houston, TX, USA; Department of Biology, Baylor University, Waco, TX, USA; Sabin Vaccine Institute, Washington, DC, USA.

Abstract

A human hookworm vaccine is under development and in clinical trials in Africa and the Americas. The vaccine contains the Na-APR-1 and Na-GST-1 antigens. It elicits neutralizing antibodies that interfere with establishment of the adult hookworm in the gut and the ability of the parasite to feed on blood. The vaccine target product profile is focused on the immunization of children to prevent hookworm infection and anemia caused by Necator americanus. It is intended for use in low- and middle-income countries where hookworm is highly endemic and responsible for at least three million disability-adjusted life years. So far, the human hookworm vaccine is being developed in the non-profit sector through the Sabin Vaccine Institute Product Development Partnership (PDP), in collaboration with the HOOKVAC consortium of European and African partners. We envision the vaccine to be incorporated into health systems as part of an elimination strategy for hookworm infection and other neglected tropical diseases, and as a means to reduce global poverty and address the Sustainable Development Goals.

KEYWORDS:

Hookworm; Necator; Neglected tropical disease; Vaccine

PMID:
27040400
DOI:
10.1016/j.vaccine.2016.03.078
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center